Cantillon Capital Management LLC Sells 35,370 Shares of Zoetis Inc. $ZTS

Cantillon Capital Management LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 2.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,219,095 shares of the company’s stock after selling 35,370 shares during the quarter. Cantillon Capital Management LLC’s holdings in Zoetis were worth $190,118,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Sound Income Strategies LLC grew its stake in shares of Zoetis by 54.3% in the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after buying an additional 152 shares in the last quarter. Canoe Financial LP boosted its position in Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio bought a new stake in Zoetis during the first quarter worth approximately $22,891,000. Tandem Investment Advisors Inc. boosted its position in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Finally, Soros Capital Management LLC boosted its position in Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after purchasing an additional 4,230 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.7%

Shares of ZTS stock opened at $146.13 on Wednesday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $189.98. The firm has a market cap of $64.76 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 2.33 and a beta of 0.90. The stock has a 50 day moving average of $148.58 and a 200-day moving average of $153.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the company earned $1.56 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 34.42%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. UBS Group decreased their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research report on Monday. Finally, Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.